skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Oligomannose Glycopeptide Conjugates Elicit Antibodies Targeting the Glycan Core Rather than Its Extremities

Journal Article · · ACS Central Science
 [1];  [1];  [2];  [1];  [1];  [1];  [3];  [4];  [4]; ORCiD logo [3];  [2]; ORCiD logo [1]
  1. Department of Chemistry, Brandeis University, Waltham, Massachusetts 02454-9110, United States
  2. Department of Integrative Structural and Computational Biology and the Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California 92037, United States
  3. Department of Biochemistry, Center for Biomedical Mass Spectrometry, Boston University School of Medicine, Boston, Massachusetts 02215, United States
  4. Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, United States

Up to ~20% of HIV-infected individuals eventually develop broadly neutralizing antibodies (bnAbs), and many of these antibodies (~40%) target a region of dense high-mannose glycosylation on gp120 of the HIV envelope protein, known as the “high-mannose patch” (HMP). Thus, there have been numerous attempts to develop glycoconjugate vaccine immunogens that structurally mimic the HMP and might elicit bnAbs targeting this conserved neutralization epitope. Herein, we report on the immunogenicity of glycopeptides, designed by in vitro selection, that bind tightly to anti-HMP antibody 2G12. By analyzing the fine carbohydrate specificity of rabbit antibodies elicited by these immunogens, we found that they differ from some natural human bnAbs, such as 2G12 and PGT128, in that they bind primarily to the core structures within the glycan, rather than to the Manα1 → 2Man termini (2G12) or to the whole glycan (PGT128). Antibody specificity for the glycan core may result from extensive serum mannosidase trimming of the immunogen in the vaccinated animals. This finding has broad implications for vaccine design aiming to target glycan-dependent HIV neutralizing antibodies.

Research Organization:
SLAC National Accelerator Lab., Menlo Park, CA (United States)
Sponsoring Organization:
USDOE Office of Science (SC), Basic Energy Sciences (BES); National Inst. of Health; USDOE Office of Science (SC), Biological and Environmental Research (BER)
Grant/Contract Number:
AC02-76SF00515; HHSN27201100016C; P41GM103393
OSTI ID:
1493660
Alternate ID(s):
OSTI ID: 1508820
Journal Information:
ACS Central Science, Journal Name: ACS Central Science Vol. 5 Journal Issue: 2; ISSN 2374-7943
Publisher:
American Chemical SocietyCopyright Statement
Country of Publication:
United States
Language:
English
Citation Metrics:
Cited by: 26 works
Citation information provided by
Web of Science

References (71)

Systematic Synthesis and Binding Study of HIV V3 Glycopeptides Reveal the Fine Epitopes of Several Broadly Neutralizing Antibodies journal April 2017
Altering the Specificity of the Antibody Response to HIV gp120 with a Glycoconjugate Antigen journal April 2016
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 journal November 2011
Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort journal January 2016
Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16 journal May 2013
The effect of Fc glycan forms on human IgG2 antibody clearance in humans journal November 2008
N-glycan PK Profiling Using a High Sensitivity nanoLCMS Work-Flow with Heavy Stable Isotope Labeled Internal Standard and Application to a Preclinical Study of an IgG1 Biopharmaceutical journal May 2015
Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans journal May 2013
Broad neutralization coverage of HIV by multiple highly potent antibodies journal September 2011
Announcing the worldwide Protein Data Bank journal December 2003
Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design journal March 2016
Structural Delineation of a Quaternary, Cleavage-Dependent Epitope at the gp41-gp120 Interface on Intact HIV-1 Env Trimers journal May 2014
Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors journal October 2013
A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity journal September 2010
Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12 journal September 2005
Toward a Carbohydrate-Based HIV-1 Vaccine:  Synthesis and Immunological Studies of Oligomannose-Containing Glycoconjugates journal March 2006
Structure and Immune Recognition of the HIV Glycan Shield journal May 2018
An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions journal October 2008
Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens journal July 2010
A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies journal September 2013
Synthesis of multivalent glycopeptide conjugates that mimic an HIV epitope journal October 2016
Characterization of a soluble class I α-mannosidase in human serum journal April 1999
Bacterially derived synthetic mimetics of mammalian oligomannose prime antibody responses that neutralize HIV infectivity journal November 2017
Proof of principle for epitope-focused vaccine design journal February 2014
Chemical Synthesis of Highly Congested gp120 V1V2 N -Glycopeptide Antigens for Potential HIV-1-Directed Vaccines journal August 2013
A Blueprint for HIV Vaccine Discovery journal October 2012
Unprecedented Role of Hybrid N- Glycans as Ligands for HIV-1 Broadly Neutralizing Antibodies journal March 2018
Production, characterization and pharmacokinetic properties of antibodies with N-linked Mannose-5 glycans journal July 2012
Site-Selective Chemoenzymatic Glycosylation of an HIV-1 Polypeptide Antigen with Two Distinct N-Glycans via an Orthogonal Protecting Group Strategy journal July 2016
Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination journal October 2016
Antibody 2G12 Recognizes Di-Mannose Equivalently in Domain- and Nondomain-Exchanged Forms but Only Binds the HIV-1 Glycan Shield if Domain Exchanged journal August 2010
A Stepwise Huisgen Cycloaddition Process: Copper(I)-Catalyzed Regioselective “Ligation” of Azides and Terminal Alkynes journal July 2002
Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates journal February 2017
Glycoengineering HIV-1 Env creates ‘supercharged’ and ‘hybrid’ glycans to increase neutralizing antibody potency, breadth and saturation journal May 2018
Fully Synthetic Carbohydrate HIV Antigens Designed on the Logic of the 2G12 Antibody journal September 2007
HIV-1 neutralizing antibodies induced by native-like envelope trimers journal June 2015
Transplanting Supersites of HIV-1 Vulnerability journal July 2014
SELMA: Selection with Modified Aptamers journal June 2015
Antibody responses to envelope glycoproteins in HIV-1 infection journal May 2015
Very Few Substitutions in a Germ Line Antibody Are Required To Initiate Significant Domain Exchange journal August 2010
HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen journal March 2016
Cross-Clade HIV-1 Neutralizing Antibodies Induced with V3-Scaffold Protein Immunogens following Priming with gp120 DNA journal July 2011
Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies journal August 2016
Antibodies elicited by yeast glycoproteins recognize HIV-1 virions and potently neutralize virions with high mannose N-glycans journal September 2015
Synthetic multivalent V3 glycopeptides display enhanced recognition by glycan-dependent HIV-1 broadly neutralizing antibodies journal January 2017
Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein journal March 2016
Antibody recognition of HIV and dengue glycoproteins journal March 2016
Antibody Domain Exchange Is an Immunological Solution to Carbohydrate Cluster Recognition journal June 2003
Overview of the development and current use of CRM197 conjugate vaccines for pediatric use journal June 2010
Defining Criteria for Oligomannose Immunogens for HIV Using Icosahedral Virus Capsid Scaffolds journal April 2010
Synthetic Three-Component HIV-1 V3 Glycopeptide Immunogens Induce Glycan-Dependent Antibody Responses journal December 2017
Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancer journal January 2013
The Glycan Shield of HIV Is Predominantly Oligomannose Independently of Production System or Viral Clade journal August 2011
Hyperglycosylated Stable Core Immunogens Designed To Present the CD4 Binding Site Are Preferentially Recognized by Broadly Neutralizing Antibodies journal December 2014
Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches journal June 2017
Yeast-Elicited Cross-Reactive Antibodies to HIV Env Glycans Efficiently Neutralize Virions Expressing Exclusively High-Mannose N-Linked Glycans journal October 2010
Dynamics of B cells in germinal centres journal February 2015
Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies journal October 2012
A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield journal October 2011
Directed Evolution of 2G12‐Targeted Nonamannose Glycoclusters by SELMA journal November 2013
Structural Evolution of Glycan Recognition by a Family of Potent HIV Antibodies journal September 2014
Structure of 2G12 Fab2 in Complex with Soluble and Fully Glycosylated HIV-1 Env by Negative-Stain Single-Particle Electron Microscopy journal June 2014
Recent strategies targeting HIV glycans in vaccine design journal November 2014
Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120 journal May 2013
Multivalent Glycocluster Design through Directed Evolution journal October 2011
Synthetic glycopeptides reveal the glycan specificity of HIV-neutralizing antibodies journal June 2013
An Expanded Set of Amino Acid Analogs for the Ribosomal Translation of Unnatural Peptides journal October 2007
Directed Evolution of Multivalent Glycopeptides Tightly Recognized by HIV Antibody 2G12 journal February 2014
High Temperature SELMA: Evolution of DNA-Supported Oligomannose Clusters Which Are Tightly Recognized by HIV bnAb 2G12 journal January 2014
Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide journal March 2017
A Glycoconjugate Antigen Based on the Recognition Motif of a Broadly Neutralizing Human Immunodeficiency Virus Antibody, 2G12, Is Immunogenic but Elicits Antibodies Unable To Bind to the Self Glycans of gp120 journal April 2008